Celemics, Inc. (KOSDAQ: 331920)

Market Cap	35.60B
Revenue (ttm)	6.08B
Net Income (ttm)	11.01B
Shares Out	8.16M
EPS (ttm)	1,347.53
PE Ratio	3.24
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,705
Open	4,400.00
Previous Close	4,345.00
Day's Range	4,285.00 - 4,445.00
52-Week Range	2,745.00 - 10,400.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Celemics

Celemics, Inc. designs, manufactures, and distributes sequencing kits. The company offers BRCA, somatic mutation cancer, and hereditary cancer kits; and NGS Library preparation kits. It also provides customized target enrichment kit, next generation sequencing, NGS unit, and NGS-lab building consulting services. The company was founded in 2010 and is based in Seoul, South Korea.

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2010
• Employees: 39
• Stock Exchange: KOSDAQ
• Ticker Symbol: 331920

Financial Performance

In 2023, Celemics's revenue was 6.58 billion, a decrease of -24.65% compared to the previous year's 8.73 billion. Losses were -3.88 billion, -19.21% less than in 2022.